Cis-Diaminedichloroplatinum

Cisplatin Platinum Ammine Chloride Trans-Diaminedichloroplatinum

Therapeutic Indications

Cis-Diaminedichloroplatinum is indicated for:

Small cell carcinoma of lung

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

In the treatment of small cell lung carcinoma.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-120 mg/m² once every 3-4 weeks

Treatment 2: Intravenous - 15-20 mg/m² once for 5 days every 3-4 weeks

Non-small cell lung cancer

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

In the treatment of advanced non-small cell lung carcinoma.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-120 mg/m² once every 3-4 weeks

Treatment 2: Intravenous - 15-20 mg/m² once for 5 days every 3-4 weeks

Head and neck squamous-cell epithelioma

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours of head and neck squamous-cell epithelioma (palliative therapy).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-120 mg/m² once every 3-4 weeks

Treatment 2: Intravenous - 15-20 mg/m² once for 5 days every 3-4 weeks

Testicular carcinoma

Men inly, only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours of testicular carcinoma (palliative and curative poly-chemotherapy).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-120 mg/m² once every 3-4 weeks

Treatment 2: Intravenous - 15-20 mg/m² once for 5 days every 3-4 weeks

Ovary carcinoma

Women only, only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours of ovary carcinoma (stages III and IV).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-120 mg/m² once every 3-4 weeks

Treatment 2: Intravenous - 15-20 mg/m² once for 5 days every 3-4 weeks

Contraindications

Active ingredient Cis-Diaminedichloroplatinum is contraindicated in the following cases:

Renal impairment

No gender/age discrimination

Yellow fever vaccine

No gender/age discrimination

Lactation

No gender/age discrimination

Cisplatin is excreted in human milk. Breastfeeding during the therapy is contraindicated.

Pregnancy

No gender/age discrimination

There are no adequate data from the use of cisplatin in pregnant women, but based on its pharmacological properties cisplatin is suspected to cause serious birth defects. Studies in animals have shown reproductive toxicity and transplacental carcinogenicity. Cisplatin is contraindicated during the pregnancy period.

Hearing impairment

No gender/age discrimination

Dehydrated condition

No gender/age discrimination

Myelosuppression

No gender/age discrimination